HC Wainwright Has Pessimistic View of Genmab A/S Q2 Earnings

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Investment analysts at HC Wainwright cut their Q2 2026 earnings per share estimates for shares of Genmab A/S in a research note issued on Wednesday, October 15th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of $0.61 per share for the quarter, down from their previous forecast of $0.62. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.45 per share. HC Wainwright also issued estimates for Genmab A/S’s Q3 2026 earnings at $0.63 EPS, Q4 2026 earnings at $0.66 EPS and FY2026 earnings at $2.26 EPS.

Several other equities research analysts have also issued reports on GMAB. Guggenheim upgraded Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price target for the company in a report on Tuesday, September 23rd. Zacks Research raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 2nd. Wall Street Zen downgraded Genmab A/S from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Truist Financial raised their price objective on Genmab A/S from $45.00 to $46.00 and gave the company a “buy” rating in a research note on Tuesday, July 8th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Genmab A/S in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Genmab A/S has a consensus rating of “Moderate Buy” and an average price target of $40.80.

Genmab A/S Price Performance

Shares of Genmab A/S stock opened at $33.17 on Friday. The firm has a market cap of $21.30 billion, a price-to-earnings ratio of 16.67, a P/E/G ratio of 1.83 and a beta of 0.98. Genmab A/S has a 52-week low of $17.24 and a 52-week high of $33.65. The stock has a 50-day simple moving average of $27.95 and a 200-day simple moving average of $23.33.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.15. The business had revenue of $925.00 million during the quarter, compared to analyst estimates of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Foresight Group Ltd Liability Partnership bought a new position in Genmab A/S in the 1st quarter worth approximately $954,000. Vident Advisory LLC bought a new stake in shares of Genmab A/S during the first quarter valued at approximately $242,000. GAMMA Investing LLC increased its position in shares of Genmab A/S by 1,465.3% during the first quarter. GAMMA Investing LLC now owns 33,482 shares of the company’s stock valued at $656,000 after purchasing an additional 31,343 shares during the period. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Genmab A/S during the second quarter valued at approximately $257,000. Finally, DAVENPORT & Co LLC increased its position in shares of Genmab A/S by 6.8% during the second quarter. DAVENPORT & Co LLC now owns 33,826 shares of the company’s stock valued at $699,000 after purchasing an additional 2,147 shares during the period. 7.07% of the stock is owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.